AUS
NZ
UK
CA
USA
IND
Highlights
- Strategic Partnership: Dimerix has signed an exclusive agreement with Japan’s FUSO Pharmaceutical Industries Ltd for the development and commercialization of DMX-200 in Japan.
- Major Financial Boost: The deal includes up to ¥10.5 billion (A$107 million) in milestone payments and royalties for Dimerix.
- Market Response: Dimerix shares surged 19.72%, trading at 42.5 cents by 10:35 AEDT.
Dimerix Ltd (ASX:DXB) has secured a strategic partnership with Japanese pharmaceutical company FUSO Pharmaceutical Industries Ltd to accelerate the development and commercialization of its lead drug candidate, DMX-200, for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.
Under the terms of the exclusive development and license agreement, FUSO will gain sole rights to develop, register, and commercialize DMX-200 in Japan. Importantly, FUSO will bear all clinical trial costs within the country, ensuring the drug’s progression without financial strain on Dimerix. The candidate is currently undergoing Phase 3 global clinical trials, with a blinded interim analysis scheduled for August 2025.
Financial and Strategic Benefits
Dimerix is set to receive up to ¥10.5 billion (A$107 million) in upfront, development, and sales milestone payments, along with royalties from future sales in Japan. This significant financial injection bolsters Dimerix’s ability to focus on its other markets, where it retains full commercialization rights outside agreements with FUSO, Advanz Pharma, and Taiba.
The partnership with FUSO leverages the Japanese company’s expertise in pharmaceutical development, particularly its established track record in sales and marketing within the renal disease segment.
CEO’s Remarks
Dr. Nina Webster, CEO and Managing Director of Dimerix, expressed confidence in the collaboration.
“FUSO brings a wealth of experience in pharmaceutical development and sales, particularly for patients with renal disease. We are pleased to partner with them to progress DMX-200 in Japan,” she said.
Positive Market Reaction
The announcement of the deal sent Dimerix shares soaring by 19.72%, reaching 42.5 cents by 10:35 AEDT. The strong market response reflects investor optimism regarding the financial and strategic potential of this partnership.
